Synonyms: BOS-172722 | compound 36 [PMID: 30199249]
Compound class:
Synthetic organic
Comment: BOS172722 is a lead inhibitor of TTK (Mps1), a dual-specificity kinase that plays a central role in mitosis and is upregulated in a range of tumour types [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
BOS172722 was advanced to clinical evalution to determine anti-tumour potential in combination with paclitaxel. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03464058 | Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects | Phase 1 Interventional | Boston Pharmaceuticals | ||
NCT03328494 | Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies | Phase 1 Interventional | Boston Pharmaceuticals |